2026-01-24 - Analysis Report
**Company Overview:**
JPMorgan Chase is a multinational bank with a diversified range of financial services including corporate and investment banking, commercial banking, and asset management.

**Return Rate Comparison:**
|  | Cumulative Return | Divergence | Relative Divergence |
| --- | --- | --- | --- |
| JPM | **194.01%** | 67.60 | 73.40% |
| VOO (S&P 500) | **126.41%** | - | - |

**Degree of Divergence:** The review stock (JPM) has a higher cumulative return than the comparison stock (VOO). The divergence is at 67.60 with a relative divergence of 73.40%.

**Alpha, Beta Analysis:**
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | **27.0%** | **17.9%** | **15.0%** | **1.2** | **265.8B** |
| 2017-2019  | **34.0%** | **17.9%** | **8.0%** | **1.1** | **379.5B** |
| 2018-2020  | **-7.0%** | **42.1%** | **-31.0%** | **1.2** | **345.9B** |
| 2019-2021  | **48.0%** | **42.1%** | **-17.0%** | **1.2** | **431.1B** |
| 2020-2022  | **-9.0%** | **41.9%** | **-16.0%** | **1.1** | **365.1B** |
| 2021-2023  | **32.0%** | **32.3%** | **11.0%** | **0.9** | **463.1B** |
| 2022-2024  | **83.0%** | **27.9%** | **53.0%** | **0.9** | **652.5B** |
| 2023-2025  | **164.0%** | **23.9%** | **89.0%** | **0.9** | **877.2B** |

**Stock Price Fluctuations:**
| Metric | Value |
| --- | --- |
| Close | **$297.72** |
| Last-Market | **-1.95%** |
| 5-day SMA | **$303.72** |
| 20-day SMA | **$318.88** |
| 60-day SMA | **$313.43** |

**Indicators and Analysis:**

| Indicator | Value |
| --- | --- |
| RSI | **28.31** |
| PPO | **-1.04** |
| Market Risk Indicator (MRI) | **0.70** |
| Hybrid Signal | Buy (Cash 0%) |
| Risk Level | Medium |
| Recent Relative Divergence Change | **-7.80** |
| 7-day Rank Change | **+63** |
| 7-day Dynamic Expected Return Change | **+32.50** |
| Expected Return (%) | **9.80%** |

**Recent News & Significant Events:**

* JPMorgan Chase (JPM) Pounds the Table on Defense Stocks - TipRanks (news)
* Intellia Therapeutics (NTLA) Is Up 6.5% After ARK’s Stock Buying And JPM Pipeline Update – Has The Bull Case Changed? - Yahoo Finance (news)
* JPMorgan Chase Stock: Post-Earnings Weakness Is An Opportunity (NYSE:JPM) - Seeking Alpha (news)
* Jim Cramer Isn’t Happy About JPMorgan (JPM) CEO Staying on For Five Years - Yahoo Finance (news)
* JPMorgan Chase Stock (JPM) Defies Trump’s $5B ‘Debanking’ Lawsuit - TipRanks (news)
* JPMorgan (JPM) Beats Earnings Estimates, TD Cowen Reaffirms Buy - Yahoo Finance (news)

**Analyst Opinions:**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.27 (~Buy)
- Opinions: 23
- Target Price (avg/high/low): **342.57** / **400.00** / **280.00**

**Comprehensive Analysis (Summary):**
JPMorgan Chase has shown a higher cumulative return of 194.01% compared to the S&P 500 (126.41%), resulting in a divergence of 67.60 and a relative divergence of 73.40%. The Alpha, Beta analysis shows a mix of high and low returns across different years. The stock price fluctuations suggest a decline in the last market with a 5-day SMA of **$303.72** and a 20-day SMA of **$318.88**. The indicators point towards a buy signal with a Market Risk Indicator of **0.70** and an Expected Return of **9.80%**. Recent news and significant events indicate positive developments such as beating earnings estimates and defying Trump's lawsuit. However, Analyst Opinions suggest a mean rating of 2.27 (~Buy) with a target price of **342.57**.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.